EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma

Harumi Sakae, Yuri Ogiso, Masaya Matsuda iD, Hayato Shimora, Tye Deering, Todd E Fox iD, Mark Kester, Takeshi Nabe, Kazuyuki Kitatani iD

Cells · 11.02.2023 · 12 (4) · 591

DOI: 10.3390/cells12040591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 11.02.2023. Verfasst von Harumi Sakae und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata 573-0101, Japan. Hauptthemen laut MEDLINE: Asthma, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceramides are an emerging class of anti-inflammatory lipids, and nanoscale ceramide-delivery systems are potential therapeutic strategies for inflammatory diseases. This study investigated the therapeutic effects of ceramide nanoliposomes (CNL) on type 2 inflammation-based asthma, induced by repeated ovalbumin (OVA) challenges. Asthmatic mice intratracheally treated with ceramide-free liposomes (Ghost) displayed typical airway remodeling including mucosal accumulation and subepithelial fibrosis, whereas, in CNL-treated mice, the degree of airway remodeling was significantly decreased. Compared to the Ghost group, CNL treatment unexpectedly failed to significantly influence formation of type 2 cytokines, including IL-5 and IL-13, known to facilitate pathogenic production of airway mucus predominantly comprising MUC5AC mucin. Interestingly, CNL treatment suppressed OVA-evoked hyperplasia of MUC5AC-generating goblet cells in the airways. This suggests that CNL suppressed goblet cell hyperplasia and airway mucosal accumulation independently of type 2 cytokine formation. Mechanistically, CNL treatment suppressed cell growth and EGF-induced activation of Akt, but not ERK1/2, in a human lung epithelial cell culture system recapitulating airway goblet cell hyperplasia. Taken together, CNL is suggested to have therapeutic effects on airway remodeling in allergic asthma by targeting goblet cell hyperplasia. These findings raise the potential of ceramide-based therapies for airway diseases, such as asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntineoplastic AgentsHumansAnimalsMiceHyperplasiaAirway RemodelingBronchoalveolar Lavage FluidLungCytokines

Stichwörter der Autor:innen

EGFasthmaceramideceramide nanoliposomegoblet cellinflammation

Substanzen

CytokinesAntineoplastic Agents

Autor:innen und Institutionen

  • Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata 573-0101, Japan.
  • Department of Pharmacology, University of Virginia, Charlottesville, VA 22908-8735, USA.

ORCID-Profile: Masaya Matsuda, Todd E Fox, Kazuyuki Kitatani

Förderung

  • JSPS KAKENHI

Zitieren

APA

Sakae, H., Ogiso, Y., Matsuda, M., Shimora, H., Deering, T., Fox, T. E., Kester, M., Nabe, T., & Kitatani, K. (2023). Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma. Cells, 12(4), 591. https://doi.org/10.3390/cells12040591

Vancouver

Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, Fox TE, et al. Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma. Cells. 2023;12(4):591. doi:10.3390/cells12040591

BibTeX
@article{Sakae2023,
  author = {Sakae, Harumi and Ogiso, Yuri and Matsuda, Masaya and Shimora, Hayato and Deering, Tye and Fox, Todd E and Kester, Mark and Nabe, Takeshi and Kitatani, Kazuyuki},
  title = {Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {591},
  doi = {10.3390/cells12040591}
}
Kostenlos starten →